HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas^[1][2].

HPV16 E7 (86-93) specific T cells are expandable upon IVS (in vitro stimulation) with cognate peptide-pulsed dendritic cells (DCs) and are reactive against peptide-pulsed targets or, in case of the E711-20 epitope-specific T cells, against HPV16 E7 expressing CaSki cell line^[1].
For peptide HPV16 E7 (86-93), the only response against K562 cells pulsed with the corresponding peptide was significantly blocked by anti-HLA class I Ab w6/32, which was not the case for HPV16 E7 expressing tumor cell line CaSki. Precursor T cells specific for HPV16 E7 (86-93) peptide is able to differentiate, at least in vitro, into HPVspecific effector cells^[1].
HPV16 E7 peptide-loaded autologous dendritic cells (DCs) are able to stimulate a specific cytotoxic CD8+ T-cell response^[2].

HPV16 E7 (86-93) peptide in IVS culture has specific T cell expansion. The HPV16 E7 (86-93) specific T cells produced does not recognize naturally HPV16 E7 expressing cell line CaSki. HPV16 E7 (86-93) peptides also has similar observations in transgenic mice. The HPV16 E7 (86-93) peptide is able to induce cytotoxic T lymphocyte (CTL) responses if loaded on the antigen presenting HLA class I molecules, but that the peptide appears not to be processed or presented by HPV16 infected cells^[1].

929.06

Solid

C₃₉H₆₇F₃N₈O₁₂S

Thr-Leu-Gly-Ile-Val-Cys-Pro-Ile

TLGIVCPI

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

DMSO : 100 mg/mL(107.64 mM;Need ultrasonic)

H₂O : 6.67 mg/mL(7.18 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.5 mg/mL (2.69 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (2.69 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.5 mg/mL (2.69 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (2.69 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.5 mg/mL (2.69 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (2.69 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。